Animascope is a company providing multimodality imaging services to international customers. Animascope experts have several years of experience in discovery and preclinical imaging in vivo.
Preclinical imaging technologies support the development of innovative diagnostic, prognostic and therapeutic applications. Noninvasive in vivo imaging technologies play a crucial role in understanding the underlying physiopathology of human diseases through real-time acquisition, processing and quantification of whole-body images.
Preclinical imaging studies are therefore of great interest for the development of new pharmaceuticals through the use of a broad range of existing methodologies and the development of new diagnostic and therapeutic options for the management of pathologies.
In biomedical research, non-invasive in vivo imaging is applicable to exploratory research and bridges the gap between preclinical and clinical research. In R&D, imaging is particularly useful for pathophysiology, drug efficacy evaluation and model validation studies. In contrast to the conventional ex vivo techniques (i.e. immunohistological techniques), in vivo imaging techniques are non-invasive and can therefore be used to perform longitudinal and dynamic studies. Indeed, the use of these tools minimises the intra- and interspecies experimental variability, greatly reduces the need for an elevated number of animals, and curtails the time to perform a given experiment. Non-invasive in vivo imaging is a cost and time-effective approach to streamline R&D and increase predictability of clinical outcomes.
Preclinical medical imaging is applicable to dynamic distribution and biomarker validation studies, and assessment of the delivery, liberation, efficacy and safety of drugs, biologics, biopharmaceuticals, nanoparticles, biomaterials and stem/progenitor cells.
New imaging technologies will ultimately contribute to identify important biomarkers and surrogate endpoints both for preclinical and clinical research. For instance, neuroimaging is now central to research and drug development in the neurosciences since it can be used to detect the pharmacological and physiological consequences of drug action within the living brain. Imaging is also essential to diagnose cancers. However this technology is not only useful to detect and localise the tumours, it is also a fundamental instrument to determine the progression and evolution of cancer and response to treatment.
Because a single modality cannot answer all questions, a multimodal approach is crucial. With multi-modality imaging, multiple experimental readouts (anatomy, biodistribution, efficacy, safety and kinetics) are available within the frame of the same study, in the same anatomical context.
Multidisciplinary expertise and several years of practice are required to develop effective capabilities in non-invasive biomedical 3D imaging exploratory research. In this context, Animascope was founded to provide state-of-the-art multimodality imaging services to international customers: optical imaging, ultrasound imaging (US), X-ray computed tomography (CT), positron emission tomography (PET), single photon emission computed tomography (SPECT) and such as magnetic resonance imaging (MRI).
Animascope services bring ethical and cost advantages to your study and help you save a significant amount of time in the R&D process, accelerating the transfer of a potential new drug from the preclinical stage to the market. To find out more, visit www.animascope.euand give your study a new look.